TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 333077

Group type: EXPERIMENTAL
Intervention: Liberal sodium bicarbonate treatment (5 to 15 mEq bicarbonate/dl 10% glucose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Restricted sodium bicarbonate treatment
Number of subjects: 62
Study: 31370154

Group type: EXPERIMENTAL
Intervention: FFE-50× at 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FFE-10× at 1200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FFE-50× at 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FFE-10× at 600 mg
Number of subjects: 10
Study: 28365118

Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 3 days (MGD3)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 7 days (MGD7)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 14 days (MGD14)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 21 days (MGD21)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control diet (CTRL; 92% chopped grass hay and 8% mineral and vitamin supplement on a dry matter basis)
Number of subjects: 25
Study: 25262164

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy (group A)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Chemotherapy (group B)
Number of subjects: 103
Study: 23088524

Group type: EXPERIMENTAL
Intervention: Hyaluronan gels applied during the first 2 weeks after SRP (n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: SRP only (control group, n = 17)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 21282661

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise training)
Number of subjects: 120
Study: 19141719

Group type: EXPERIMENTAL
Intervention: Digital off‐loading silicone padding
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 89
Study: 16770728

Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg daily for 6 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (daily for 6 weeks)
Number of subjects: 9
Study: 15309735

Group type: EXPERIMENTAL
Intervention: Lipiodol perfusion group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iodized oil perfusion group
Number of subjects: 100
Study: 11512691

Group type: EXPERIMENTAL
Intervention: Late systolic wave observed in brachial artery Doppler study in CAD patients
Number of subjects: 96

Group type: COMPARATOR
Intervention: Healthy subjects without late systolic wave
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Comparison of risk factors
Number of subjects: 96
Study: 8996149

Group type: EXPERIMENTAL
Intervention: Chemotherapy with six cycles of 5FU (425 mg/m2) plus leucovorin (20 mg/m2) by rapid intravenous injection daily for 5 consecutive days every 4 to 5 weeks
Number of subjects: 317

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 317
Study: 7837147

Group type: EXPERIMENTAL
Intervention: Circulating endothelin-1 (sET-1) levels in patients with diffuse systemic sclerosis (dSSc)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Circulating endothelin-1 (sET-1) levels in patients with primary Raynaud's phenomenon (RP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Circulating endothelin-1 (sET-1) levels in patients with limited cutaneous systemic sclerosis (lcSSc) with hypertensive lung or renal disease
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Correlation of sET-1 levels with plasma von Willebrand factor (vWF), skin fibrosis (skin score), and duration of disease in patients with SSc
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Comparison of sET-1 levels in diffuse cutaneous disease (dcSSc) with fibrotic dermal or lung pathology versus additional PHT or HRC crisis
Number of subjects: 64
Study: 3367432

Group type: EXPERIMENTAL
Intervention: Partial graft removal
Number of subjects: 75

Group type: COMPARATOR
Intervention: Complete graft removal
Number of subjects: 75
Study: 31980445

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia at 36 weeks postmenstrual age
Number of subjects: 412
Study: 29202263

Group type: COMPARATOR
Intervention: Alloplast (n=11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Allograft (n=12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Alloplast (large particle size)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Allograft (large particle size)
Number of subjects: 23
Study: 28582279

Group type: EXPERIMENTAL
Intervention: High NRG1 expression
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: High HER3 expression
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: High HER2/neu expression
Number of subjects: 208
Study: 25307979

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 36
Study: 23343818

Group type: EXPERIMENTAL
Intervention: Hamstring muscle extensibility in maximal trunk flexion with knees flexed
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hamstring muscle extensibility in sit-and-reach test for thoracic spine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hamstring muscle extensibility in sit-and-reach test for pelvic tilt
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hamstring muscle extensibility in standing and on the bicycle postures
Number of subjects: 75
Study: 21199130

Group type: EXPERIMENTAL
Intervention: 0.5 mg·kg(‐1) ketorolac IV
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1 mg·kg(‐1) ketorolac IV
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18272930

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) beverage
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein (CHO+PRO) beverage
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PLA) beverage
Number of subjects: 18
Study: 16946218

Group type: EXPERIMENTAL
Intervention: Vaginal (dry) misoprostol 400 mug
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaginal (moistened) misoprostol 400 mug
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 400 mug
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 400 mug
Number of subjects: 40
Study: 12697917

Group type: EXPERIMENTAL
Intervention: Urinary interleukin-8 (IL-8) measurement
Number of subjects: 208
Study: 10776826

Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg/day orally
Number of subjects: 3
Study: 8615509

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mivacurium 0.2 mg/kg
Number of subjects: 30
Study: 1598824

Group type: EXPERIMENTAL
Intervention: Tablet A (300 mg ofloxacin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tablet B (300 mg ofloxacin)
Number of subjects: 12
Study: 6507576

Group type: EXPERIMENTAL
Intervention: Armorlite Multiple Drop
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Signet Hyperaspheric
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sola Hi-Drop
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: American Optical Fulvue
Number of subjects: 11

Group type: COMPARATOR
Intervention: All lens types
Number of subjects: 11
Study: 31372571

Group type: EXPERIMENTAL
Intervention: Picture This! intervention
Number of subjects: 0
Study: 29397361

Group type: EXPERIMENTAL
Intervention: Cognitive assessments including attention, processing speed, executive function, verbal and visual memory; mean composite z-score of -0.65 SD below normative mean.
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: FLAIR lesion volume
Number of subjects: 234
Study: 27305037

Group type: EXPERIMENTAL
Intervention: Hypofractionated whole‐breast irradiation (HF‐WBI) at a dose of 42.56 grays in 16 fractions plus a tumor bed boost
Number of subjects: 287

Group type: COMPARATOR
Intervention: Conventionally fractionated whole‐breast irradiation (CF‐WBI) at a dose of 50 grays in 25 fractions plus a tumor bed boost
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Both treatment arms (CF‐WBI and HF‐WBI)
Number of subjects: 287
Study: 24427769

Group type: EXPERIMENTAL
Intervention: Cold pressor test (8°C)
Number of subjects: 9
Study: 21867844

Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg/ezetimibe 10 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 68
Study: 20082247

Group type: EXPERIMENTAL
Intervention: Normal acupuncture
Number of subjects: 117

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 117
Study: 16436852

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.25%) bolus with saline infusion (group I)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.25%) bolus and infusion (group II)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Saline bolus (30 ml) plus saline infusion (270 ml at 5 ml/h, placebo group)
Number of subjects: 233
Study: 15123483

Group type: EXPERIMENTAL
Intervention: Enteral rehydration therapy
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Intravenous rehydration therapy
Number of subjects: 1545
Study: 11775647

Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9017769

Group type: EXPERIMENTAL
Intervention: Furosemide products (one intravenous and four oral tablet formulations)
Number of subjects: 17
Study: 8359793

Group type: EXPERIMENTAL
Intervention: Propranolol plus isosorbide dinitrate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 44
Study: 3674221

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (7 mg/kg)
Number of subjects: 0
Study: 1101066

Group type: EXPERIMENTAL
Intervention: High titer globulin (3 ml, repeated at four months)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Intermediate titer globulin (3 ml, repeated at four months)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Normal titer globulin (3 ml, repeated at four months)
Number of subjects: 614
Study: 31264565

Group type: EXPERIMENTAL
Intervention: Riverbank filtration-treated water delivered to newly installed water storage tanks (improved quality and access)
Number of subjects: 9836

Group type: COMPARATOR
Intervention: Unfiltered river water (improved access alone)
Number of subjects: 9836
Study: 31343801

Group type: EXPERIMENTAL
Intervention: Virtual 3D models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional 2D drawings
Number of subjects: 0
Study: 28928170

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 15
Study: 26036793

Group type: COMPARATOR
Intervention: Conventional CT scan (Group A): Tube voltage 120 kVp, automatic current modulation with a Noise Index of 12, ASIR 30%, injected with Iohexol (350 mgI/ml)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Spectral CT Imaging (Group B): Tube current of 600 mA, injected with Iodixanol (270 mgI/ml)
Number of subjects: 70
Study: 23322408

Group type: EXPERIMENTAL
Intervention: Chitosan-dextran (CD) gel applied unilaterally
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no gel applied on contralateral sides)
Number of subjects: 26
Study: 21761711

Group type: EXPERIMENTAL
Intervention: Clarithromycin (0.25 g/day, first two weeks 0.25 g twice a day) combined with Triamcinolone Acetonide Acetate nasal spray (220 microg/d once a day) for CRS with nasal polyps
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clarithromycin (0.25 g/day, first two weeks 0.25 g twice a day) combined with Triamcinolone Acetonide Acetate nasal spray (220 microg/d once a day) for CRS without nasal polyps
Number of subjects: 56
Study: 18070951

Group type: EXPERIMENTAL
Intervention: ICD Plan (intervention group)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 192
Study: 17289155

Group type: EXPERIMENTAL
Intervention: Standardized self‐report instruments and structured interviews
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Higher levels of nicotine dependence and concurrent hazardous use of alcohol or cannabis
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Reasons for smoking
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Demographic and clinical characteristics
Number of subjects: 298
Study: 15229205

Group type: EXPERIMENTAL
Intervention: Individualized GnRH antagonist regimen (flexible regimen)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard GnRH antagonist regimen (fixed regimen)
Number of subjects: 205
Study: 11704371

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 509

Group type: COMPARATOR
Intervention: PTCA (Control)
Number of subjects: 509
Study: 9205816

Group type: EXPERIMENTAL
Intervention: Intravenous administration of rhIL-11 at 10-50 micrograms kg-1 for 1 or 3 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhIL-11 at 3-50 micrograms kg-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhIL-11 at 3 micrograms kg-1 once daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhIL-11 at 50 micrograms kg-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhIL-11
Number of subjects: 0
Study: 8381643

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Clotrimazole (200 mg/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (two capsules per day)
Number of subjects: 95
Study: 2957801

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg once daily for the first 2 days, then 20 mg once daily for 5 days
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 29475433

Group type: EXPERIMENTAL
Intervention: 0.1 ml of 24% sucrose
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 0.5 ml of 24% sucrose
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 1.0 ml of 24% sucrose
Number of subjects: 245

Group type: COMPARATOR
Intervention: All sucrose doses
Number of subjects: 245
Study: 27717319

Group type: EXPERIMENTAL
Intervention: Acupuncture with medical self-care advice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Touch intervention with medical self-care advice
Number of subjects: 40
Study: 25575288

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV), 10-min sessions, 3 times a week for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham WBV, 3 times a week for 8 weeks after a 4-week washout period
Number of subjects: 16
Study: 23707316

Group type: EXPERIMENTAL
Intervention: High cholesterol absorption (measured by cholestanol-to-cholesterol ratio, CR)
Number of subjects: 4362

Group type: EXPERIMENTAL
Intervention: Cholesterol absorption (CR)
Number of subjects: 4362
Study: 20712886

Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy (1250 mg/m2 twice daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Capecitabine and vinorelbine (dose level 2)
Number of subjects: 51
Study: 18379356

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 16699663

Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase (MMP)‐9 expression in pterygium lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal Tenon's capsule
Number of subjects: 0
Study: 15298634

Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intact lansoprazole orally disintegrating tablet administered directly onto the tongue without water
Number of subjects: 40
Study: 11495870

Group type: EXPERIMENTAL
Intervention: remifentanil 2 microg x kg(‐1)
Number of subjects: 56

Group type: COMPARATOR
Intervention: remifentanil 1 microg x kg(‐1)
Number of subjects: 56
Study: 9297946

Group type: EXPERIMENTAL
Intervention: Bimanual manipulation by dentists using the same wax recording technique to determine CR.
Number of subjects: 5
Study: 8420383

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 199
Study: 3541596

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 or 20 mg orally three times daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 31020342

Group type: EXPERIMENTAL
Intervention: Short femoral stem (group 1)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Conventional femoral stem (group 2)
Number of subjects: 127
Study: 29419917

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg/d
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg/d
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo/Metformin
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 461
Study: 27884165

Group type: EXPERIMENTAL
Intervention: Computerized decision support system (CDSS) linked to electronic health records (EHRs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care without CDSS)
Number of subjects: 0
Study: 24488608

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 238

Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 238
Study: 22112818

Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Genotypes with at least one allele with ≥25% residual activity compared to wild type
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: p.R408W mutation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Alleles Y414C and I65T
Number of subjects: 74
Study: 20694775

Group type: EXPERIMENTAL
Intervention: Chinese medicine group (CM)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Western medicine group (WM)
Number of subjects: 270
Study: 18471409

Group type: EXPERIMENTAL
Intervention: Astragalous Injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 60
Study: 16869840

Group type: EXPERIMENTAL
Intervention: CBT + CE
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: CBT + ECE
Number of subjects: 163

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 163
Study: 12658207

Group type: EXPERIMENTAL
Intervention: Skeletonized internal thoracic artery graft
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pedicled internal thoracic artery graft
Number of subjects: 15
Study: 10641317

Group type: EXPERIMENTAL
Intervention: Intervention involved presenting multiple items in a rapid serial visual presentation stream with varying intertarget stimulus onset asynchrony (100 to 500 ms).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention involved manipulating the number of items competing for retrieval as T2 in the rapid serial visual presentation.
Number of subjects: 0
Study: 8678496

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Simultaneous combination of TAM & MPA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alternating sequential combination of TAM plus MPA (TAM‐MPA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: TAM & MPA
Number of subjects: 52

Group type: COMPARATOR
Intervention: TAM‐MPA
Number of subjects: 52

Group type: COMPARATOR
Intervention: MPA as second-line therapy after TAM
Number of subjects: 52

Group type: COMPARATOR
Intervention: All therapies
Number of subjects: 52
Study: 1765356

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg uid
Number of subjects: 167

Group type: COMPARATOR
Intervention: Ranitidine 150 mg bid
Number of subjects: 167
Study: 6207497

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 500

Group type: COMPARATOR
Intervention: No antibiotics (Control)
Number of subjects: 500
Study: 31323209

Group type: EXPERIMENTAL
Intervention: Prolonged Air Leak Score (PALS) > 17 points
Number of subjects: 52198

Group type: EXPERIMENTAL
Intervention: PALS
Number of subjects: 52198
Study: 30524749

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone used in conjunction with iNO
Number of subjects: 20

Group type: COMPARATOR
Intervention: iNO alone
Number of subjects: 20
Study: 27491224

Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Pill (LDP) and Ginkgo Leaf Tablet (GLT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Liuwei Dihuang Pill (placebo) and Ginkgo Leaf Tablet (placebo)
Number of subjects: 140
Study: 24317958

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CanalBrush
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: EndoActivator
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: RinsEndo
Number of subjects: 53

Group type: COMPARATOR
Intervention: Syringe irrigation (control)
Number of subjects: 53
Study: 21367473

Group type: EXPERIMENTAL
Intervention: Surgery group (bariatric surgery)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Obese group (weight stable)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Lean group (normal weight)
Number of subjects: 132
Study: 19742426

Group type: EXPERIMENTAL
Intervention: Preoperative computed tomographic (CT) angiogram (multidetector row computed tomography [MDCT])
Number of subjects: 357
Study: 17383492

Group type: EXPERIMENTAL
Intervention: Home-based intervention program (HBIP) performed 2 and 4 weeks after surgery.
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 203